(-)-Epigallocatechin-3-O-gallate (EGCG) reverses caffeine-induced anxiogenic-like effects

被引:29
|
作者
Park, Kwang-Soon
Oh, Ju Hoon
Yoo, Hwan-Soo
Lee, Yong-Moon
Lee, Myung-Koo
Hong, Jin Tae
Oh, Ki-Wan [1 ]
机构
[1] Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea
关键词
Epigallocatechin-3-O-gallate (EGCG); Caffeine; Anxiogenic; Electroencephalogram (EEG); Fast/slow waves (FW/SW) ratios; ALPHA-OSCILLATIONS; BRAIN OSCILLATIONS; ANXIETY; GALLATE; MICE;
D O I
10.1016/j.neulet.2010.06.072
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This study was designed to determine whether (-)-epigallocatethin-3-O-gallate (EGCG) could reverse caffeine-induced anxiogenic-like effects in animals. In mice, EGCG antagonized the caffeine-induced reduction in both the open arm entry number and time-spent in open arm on elevated plus-maze. In addition, EGCG also antagonized the caffeine-induced reduction in both the central zone distance and central zone time-spent on an open field apparatus, respectively. Electroencephalogram (EEG) was recorded from the rat anterior cerebral cortex. Caffeine increased the power density-ratios of fast (FW: 8.00-20.00 Hz) and slow (SW: 0.75-8.00 Hz) frequency spectrum bands in these EEG recordings. However, EGCG reduced the caffeine-induced increase of FW/SW ratios. Thus, EGCG reverses caffeine-induced anxiogenic-like effects. We also provide additional evidence that the EEG FW/SW (or SW/FW) ratios can be a useful tool for the prediction of anxiogenic and/or anxiolytic effects in an animal model. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:131 / 134
页数:4
相关论文
共 50 条
  • [11] ANXIOGENIC-LIKE EFFECTS INDUCED BY STIMULATION OF DOPAMINE-RECEPTORS
    SIMON, P
    PANISSAUD, C
    COSTENTIN, J
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 45 (03) : 685 - 690
  • [12] Epigallocatechin-3-O-gallate (EGCG) protects the insulin sensitivity in rat L6 muscle cells exposed to dexamethasone condition
    Zhang, Z. F.
    Li, Q.
    Liang, J.
    Dai, X. Q.
    Ding, Y.
    Wang, J. B.
    Li, Y.
    PHYTOMEDICINE, 2010, 17 (01) : 14 - 18
  • [13] Antiviral Mechanism of Action of Epigallocatechin-3-O-gallate and Its Fatty Acid Esters
    Kaihatsu, Kunihiro
    Yamabe, Miyuki
    Ebara, Yasuhito
    MOLECULES, 2018, 23 (10):
  • [14] Development of High-Order Functions Using (-)-Epigallocatechin-3-O-gallate in Water
    Ishizu, Takashi
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2020, 68 (12) : 1143 - 1154
  • [15] (-)-Epigallocatechin-3-O-Gallate Augments Pentobarbital-Induced Sleeping Behaviors Through Cl- Channel Activation
    Park, Kwang-Soon
    Han, Jin-Yi
    Moon, Dong-Cheul
    Hong, Jin Tae
    Oh, Ki-Wan
    JOURNAL OF MEDICINAL FOOD, 2011, 14 (11) : 1456 - 1462
  • [16] Differentiation-associated alteration in sensitivity to apoptosis induced by (-)-epigallocatechin-3-O-gallate in HL-60 cells
    Okada, Norihisa
    Tanabe, Hiroki
    Tazoe, Hideaki
    Ishigami, Yoko
    Fukutomi, Ryuuta
    Yasui, Kensuke
    Isemura, Mamoru
    BIOMEDICAL RESEARCH-TOKYO, 2009, 30 (04): : 201 - 206
  • [17] The effects of nicotine on nitric oxide induced anxiogenic-like behaviors in the dorsal hippocampus
    Piri, Morteza
    Nasehi, Mohammad
    Shahab, Zahra
    Zarrindast, Mohammad Reza
    NEUROSCIENCE LETTERS, 2012, 528 (02) : 93 - 98
  • [18] Protective effects of epigallocatechin gallate (EGCG) on streptozotocin-induced diabetic nephropathy in mice
    Yoon, Sang Ni
    Maeng, Young Hee
    Hong, Ran
    Lee, Byung Rai
    Kim, Chong Gue
    Kim, Hyun Lee
    Chung, Jong Hoon
    Shin, Byung Chul
    ACTA HISTOCHEMICA, 2014, 116 (08) : 1210 - 1215
  • [19] Suppressive effect of epigallocatechin-3-O-gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo
    Lin, Chiu-Mei
    Chang, Hang
    Wang, Bao-Wei
    Shyu, Kou-Gi
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2016, 20 (11) : 2045 - 2055
  • [20] An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice
    Belzung, C
    Le Guisquet, AM
    Barreau, S
    Calatayud, F
    BEHAVIOURAL PHARMACOLOGY, 2001, 12 (03): : 151 - 162